PACIFIC BIOSCIENCES OF CALIFORNIA, INC.
Last · NasdaqGS$2.10-0.23 (-9.87%)stale · yahoo · 58h ago
Market cap$652.74M310.8M sh
P/E · TTM-5.4fwd -5.0 · eps -0.43 · loss
Beta2.19vs S&P 500
Div yield0.00%annual · TTM
52w range
$1.07$3.44
Volume12.1Msession
| Revenue | $76.2M |
|---|---|
| Operating income | $-53.0M |
| Net income | $-53.0M |
| Free cash flow | $-84.9M |
| Operating margin | -69.5% |
| Net margin | -69.6% |
| Period | 2026 |
Loading chart…
Upcoming earnings
9:00 PM UTC+1
Period
Sep 2026
Est. EPS
−$0.13
Est. revenue
39.5M
Press & signals
- GlobeNewswire
PacBio and TychoBio Collaborate to Train AI Models for Rare Disease RNA Therapeutics
- GlobeNewswire
PacBio Appoints Mark Van Oene as President and Chief Executive Officer
- GlobeNewswire
PacBio Announces Second Quarter 2026 Financial Results
Documents
FormReporting forFiledFlags